Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $642.5 million.

  • Amphastar Pharmaceuticals' Retained Earnings rose 2102.92% to $642.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $642.5 million, marking a year-over-year increase of 2102.92%. This contributed to the annual value of $568.8 million for FY2024, which is 3897.67% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Retained Earnings stood at $642.5 million, which was up 2102.92% from $625.1 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Retained Earnings high stood at $642.5 million for Q3 2025, and its period low was $122.8 million during Q1 2021.
  • Moreover, its 5-year median value for Retained Earnings was $323.9 million (2023), whereas its average is $359.9 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Retained Earnings surged by 207.37% in 2021 and then skyrocketed by 6996.04% in 2022.
  • Over the past 5 years, Amphastar Pharmaceuticals' Retained Earnings (Quarter) stood at $180.3 million in 2021, then soared by 50.68% to $271.7 million in 2022, then skyrocketed by 50.62% to $409.3 million in 2023, then skyrocketed by 38.98% to $568.8 million in 2024, then increased by 12.95% to $642.5 million in 2025.
  • Its last three reported values are $642.5 million in Q3 2025, $625.1 million for Q2 2025, and $594.1 million during Q1 2025.